Chemotherapy-Induced Nausea and Vomiting

Cross-source consensus on Chemotherapy-Induced Nausea and Vomiting from 1 sources and 4 claims.

1 sources · 4 claims

Risks & contraindications

The trial defines complete response as no vomiting and no rescue therapy during the first 120 hours after chemotherapy starts. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial
Chemotherapy-induced nausea and vomiting is a common toxicity of cancer treatment that can affect most patients without prophylaxis. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial
Even guideline-recommended prevention does not fully control CINV in many patients receiving moderately or highly emetogenic chemotherapy. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial
Poor control of CINV can reduce quality of life and treatment adherence and may affect survival outcomes. — Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial